Imparting aromaticity to 2-pyridone derivatives by O-alkylation resulted in new competitive and non-competitive PIM-1 kinase inhibitors with caspase-activated apoptosis

References

• Wang BW, Huang CH, Liu LC, Cheng FJ, Wei YL, Lin YM, Wang YF, Wei CT, Chen Y, Chen YJ, et al. PIM1 kinase inhibitors exert anti-cancer activity against HER2-positive breast cancer cells through downregulation of HER2. Front Pharmacol. 2021;12:614673.
   PubMed Web of Science ®Google Scholar
• Puente-Moncada N, Costales P, Antolín I, Núñez L-E, Oro P, Hermosilla MA, Pérez-Escuredo J, Ríos-Lombardía N, Sanchez-Sanchez AM, Luño E, et al. Inhibition of FLT3 and PIM kinases by EC-70124 exerts potent activity in preclinical models of acute myeloid leukemia. Mol Cancer Ther. 2018;17(3):614–624.
   PubMed Web of Science ®Google Scholar
• Ogawa N, Yuki H, Tanaka A. Insights from PIM1 structure for anti-cancer drug design. Expert Opin Drug Discov. 2012;7(12):1177–1192.
   PubMed Web of Science ®Google Scholar
• Schenone S, Tintori C, Botta M. Using insights into PIM1 structure to design new anticancer drugs. Curr Pharm Des. 2010;16(35):3964–3978.
   PubMed Web of Science ®Google Scholar
• Blanco-Aparicio C, Carnero A. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol. 2013;85(5):629–643.
   PubMed Web of Science ®Google Scholar
• Mohamed EA, Ismail NSM, Hagras M, Refaat H. Medicinal attributes of pyridine scaffold as anticancer targeting agents. Futur J Pharm Sci. 2021;7(1):24.
   Web of Science ®Google Scholar
• Ye C, Zhang C, Huang H, Yang B, Xiao G, Kong D, Tian Q, Song Q, Song Y, Tan H, et al. The natural compound myricetin effectively represses the malignant progression of prostate cancer by inhibiting PIM1 and disrupting the PIM1/CXCR4 interaction. Cell Physiol Biochem. 2018;48(3):1230–1244.
   PubMedGoogle Scholar
• Liu K, Gao H, Wang Q, Wang L, Zhang B, Han Z, Chen X, Han M, Gao M. Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer. Cancer Sci. 2018;109(5):1369–1381.
   PubMed Web of Science ®Google Scholar
• Stafman LL, Mruthyunjayappa S, Waters AM, Garner EF, Aye JM, Stewart JE, Yoon KJ, Whelan K, Mroczek-Musulman E, Beierle EA. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma. Oncotarget. 2018;9(32):22665–22679.
   PubMedGoogle Scholar
• Brasó-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, Plumb DA, Zakka L, Gazinska P, Liccardi G, et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016;22(11):1303–1313.
   PubMed Web of Science ®Google Scholar
• Kronschnabl P, Grünweller A, Hartmann RK, Aigner A, Weirauch U. Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progression. Int J Oncol. 2020;56(2):448–459.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu T, Sun H, Weng W, Zhang Q, Liu C, Han Y, Sheng W. PIM1 supports human colorectal cancer growth during glucose deprivation by enhancing the Warburg effect. Cancer Sci. 2018;109(5):1468–1479.
   PubMed Web of Science ®Google Scholar
• Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX. PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest. 2009;119(2):362–375.
   PubMed Web of Science ®Google Scholar
• Li J, Hu XF, Loveland BE, Xing PX. PIM-1 expression and monoclonal antibody targeting in human leukemia cell lines. Exp Hematol. 2009;37(11):1284–1294.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang Y, Guo Y, Wang H, Fu R. An overview of PIM kinase as a target in multiple myeloma. Cancer Med. 2023;12(10):11746–11759.
   PubMed Web of Science ®Google Scholar
• Abnous K, Manavi H, Mehri S, Alibolandi M, Kamali H, Ghandadi M, Hadizadeh F. In vitro evaluation of dihydropyridine-3-carbonitriles as potential cytotoxic agents through PIM-1 protein kinase inhibition. Res Pharm Sci. 2017;12(3):196–203.
   PubMedGoogle Scholar
• Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, Zhao R, Kondo S, Wang H, Wang H, Yeung S-CJ, et al. Hypoxia-mediated up-regulation of PIM-1 contributes to solid tumor formation. Am J Pathol. 2009;175(1):400–411.
   PubMed Web of Science ®Google Scholar
• Walhekar V, Bagul C, Kumar D, Muthal A, Achaiah G, Kulkarni R. Topical advances in PIM kinases and their inhibitors: medicinal chemistry perspectives. Biochim Biophys Acta Rev Cancer. 2022;1877(3):188725.
   PubMed Web of Science ®Google Scholar
• Mori M, Tintori C, Christopher RSA, Radi M, Schenone S, Musumeci F, Brullo C, Sanità P, Delle Monache S, Angelucci A, et al. A combination strategy to inhibit PIM-1: synergism between noncompetitive and ATP-competitive inhibitors. ChemMedChem. 2013;8(3):484–496.
   PubMed Web of Science ®Google Scholar
• Morwick T. PIM kinase inhibitors: a survey of the patent literature. Expert Opin Ther Pat. 2010;20(2):193–212.
   PubMed Web of Science ®Google Scholar
• Nair JR, Caserta J, Belko K, Howell T, Fetterly G, Baldino C, Lee KP. Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma. Leukemia. 2017;31(8):1715–1726.
   PubMed Web of Science ®Google Scholar
• Wähler K, Kräling K, Steuber H, Meggers E. Non-ATP-mimetic organometallic protein kinase inhibitor. ChemistryOpen. 2013;2(5–6):180–185.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Han B-G, Cho J-W, Choi J-S, Lee J, Song H-J, Koh JS, Lee BI. Crystal structure of PIM1 kinase in complex with a pyrido[4,3-d]pyrimidine derivative suggests a unique binding mode. PLOS One. 2013;8(7):e70358.
   PubMed Web of Science ®Google Scholar
• El-Miligy MMM, Abdelaziz ME, Fahmy SM, Ibrahim TM, Abu-Serie MM, Mahran MA, Hazzaa AA. Discovery of new pyridine–quinoline hybrids as competitive and non-competitive PIM-1 kinase inhibitors with apoptosis induction and caspase 3/7 activation capabilities. J Enzyme Inhib Med Chem. 2023;38(1):2152810.
   PubMed Web of Science ®Google Scholar
• Ethics Committee. Faculty of Medicine, Alexandria University, Member of ICLAS, IRB No.: 00018699, SN: 0201797(9-4-2023); 2023.
   Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.
   PubMed Web of Science ®Google Scholar
• Xu T, Niu C, Zhang X, Dong M. B-ecdysterone protects SH-SY5Y cells against β-amyloid-induced apoptosis via c-Jun N-terminal kinase- and Akt-associated complementary pathways. Lab Invest. 2018;98(4):489–499.
   PubMed Web of Science ®Google Scholar
• Brown AM. A new software for carrying out one-way ANOVA post hoc tests. Comput Methods Prog Biomed. 2005;79(1):89–95.
   PubMed Web of Science ®Google Scholar
• Promega; 2023. Available from: https://www.promega.com/-/media/files/resources/protocols/kinase-enzyme, appnotes/pim1-kinase-assay.pdf?la=en
   Google Scholar
• Arrouchi H, Lakhlili W, Ibrahimi A. A review on PIM kinases in tumors. Bioinformation. 2019;15(1):40–45.
   PubMed Web of Science ®Google Scholar
• Hassan AS, Hafez TS, Osman SA. Synthesis, characterization, and cytotoxicity of some new 5-aminopyrazole and pyrazolo[1,5-a]pyrimidine derivatives. Sci Pharm. 2015;83(1):27–39.
   PubMedGoogle Scholar
• Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1(3):1458–1461.
   PubMed Web of Science ®Google Scholar
• Cheney IW, Yan S, Appleby T, Walker H, Vo T, Yao N, Hamatake R, Hong Z, Wu JZ. Identification and structure–activity relationships of substituted pyridones as inhibitors of PIM-1 kinase. Bioorg Med Chem Lett. 2007;17(6):1679–1683.
   PubMed Web of Science ®Google Scholar
• Sotriffer Accounting AC. For induced-fit effects in docking: what is possible and what is not? Curr Top Med Chem. 2011;11(2):179–191.
   PubMed Web of Science ®Google Scholar
• Barreca ML, Iraci N, De Luca L, Chimirri A. Induced‐fit docking approach provides insight into the binding mode and mechanism of action of HIV‐1 integrase inhibitors. ChemMedChem. 2009;4(9):1446–1456.
   PubMed Web of Science ®Google Scholar
• Nirwan S, Chahal V, Kakkar R. A comparative study of different docking methodologies to assess the protein–ligand interaction for the E. coli murb enzyme. J Biomol Struct Dyn. 2022;40(21):11229–11238.
   PubMed Web of Science ®Google Scholar
• Molinspiration; 2023. Available from: http://www.molinspiration.com/
   Google Scholar
• Molsoft; 2023. Available from: http://molsoft.com/mprop/
   Google Scholar
• Preadmet; 2023. Available from: http://preadmet.bmdrc.org/
   Google Scholar
• Hopkins AL, Keserü GM, Leeson PD, Rees DC, Reynolds CH. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov. 2014;13(2):105–121.
   PubMed Web of Science ®Google Scholar